First transplant of a whole pig liver and two kidneys into a clinically deceased man: short-term function observed
Exploring pig organs as an alternative amid organ shortages
The first case of transplanting a whole liver and two kidneys from a genetically modified pig into a 53-year-old clinically deceased man has been reported. According to a Med study covered by Nature on May 29, 2026, the procedure was performed with the family’s consent, organ function was maintained for nearly five days, and no signs of rejection of the transplanted organs were observed during the first 24 hours after transplantation. This was a short-term observation and should be distinguished from evidence of treatment benefit in a living patient.
Xenotransplantation of pig organs into humans is being studied as a potential way to ease organ shortages. Nature reported that trials using genetically modified pig organs are underway in China and the United States. This case is notable because a whole liver and two kidneys were transplanted together into one person.
Nearly five days of function; rejection observations cover the first 24 hours
The publicly available opening of the news report describes the recipient as a “clinically deceased man.” It does not provide the specific criteria for determining death, so it cannot be stated definitively that he was brain-dead. Family consent is confirmed, but the available material does not include details of the study procedures or surgical conditions.
Two observation periods must be distinguished when interpreting the results. The reported duration of organ function was nearly five days, whereas the stated absence of signs of rejection applies to the first 24 hours. It would therefore go beyond the source material to say that rejection was absent throughout nearly five days or that immune rejection was completely prevented.
The available public information does not specify which tests were used to assess liver and kidney function separately, how the measurements changed, or which immunosuppressive regimen was used. The summary that organ function was maintained is not enough to determine the functional level of each transplanted organ or its equivalence to a normal organ.
It is confirmed that the donor pig was genetically modified. However, the publicly available opening does not identify the edited genes or provide results on the handling or testing of porcine endogenous retroviruses (PERVs). The available evidence does not support presenting the removal of specific antigens or the elimination of viral transmission risk as achievements of this case.
Between the potential for organ supply and clinical proof
The short-term results in this single case provide information for exploring the possibility of transplanting pig organs into humans. Easing organ shortages is a potential future application; this observation does not establish recovery in a living patient or long-term function of the transplanted organs.
Assessing potential clinical application will require organ-specific functional measures, the time course of rejection, infection surveillance results, and the burden of immunosuppressive treatment. These are matters for follow-up investigation; this does not mean they were all evaluated in the publicly available news report. This case alone also cannot establish large-scale supply or shorter transplant waiting times.
The Nature article is news coverage, not the original research paper. The study cited by the report is Liao et al., Med 7, 101148 (2026); this account reflects only the available public opening and reference information. Original Nature report
Nature, Published online: 29 May 2026. DOI: 10.1038/d41586-026-01708-0
Summary: Bypassing the historical hyperacute immunological rejections and zoonotic viral transfer barriers that limited xenotransplantation pipelines, this multi-national investigation details trials of genetically modified porcine organs across US and Chinese clinical registries. By exploiting multiplex CRISPR-Cas9 genome editing matrices, researchers programmatically eliminated triple carbohydrate antigen codes and systematically inactivated porcine endogenous retrovirus (PERV) elements within the donor genome. This architectural modification structurally uncoupled host immune surveillance from heterologous donor organ degradation, sustaining functional metabolic fluxes and glomerular filtration rates post-transplantation without triggering off-target genotoxicity. This profile delivers a generalizable computational baseline for scalable, off-the-shelf organ supply frameworks and target human clinical translation.
This case is notable for observing short-term organ function after a whole pig liver and two kidneys were transplanted together into a human recipient. Future transplant studies can assess how well each organ functions and evaluate safety by jointly analyzing liver and kidney function tests, signs of rejection, and infection surveillance results. Accumulating such evidence will be necessary to judge whether this approach could develop into a practical treatment strategy to ease organ shortages. However, the recipient in this case was clinically deceased, and the observation period was short. The findings cannot be extended to conclude that a treatment option for living patients or a stable organ supply system has been established.